| Species |
Human |
| Protein Construction |
CD161 (Gln67-Ser225)
Accession # Q12918-1 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CD161, His, Human at 2μg/ml (100μl/Well) on the plate can bind AntiCD161 Antibody, hFc Tag. Test result was comparable to standard batch |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
19.6 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 38-45 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
CD161 (NKRP1) is a lectin-like receptor present on NK cells and rare T-cell subsets. We have observed CD161 expression in some cases of T-cell prolymphocytic leukemia (T-PLL) and found it to be useful in follow-up and detection of disease after treatment. |
| Synonyms |
KLRB1; CLEC5B; NKRP1A; NKR-P1A; HNKR-P1a; CD161; Ly59; NKR; NKRP1; NKR-P1; NKRP1ANKR |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
